AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32000729
Drug: Stepping Stones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepping Stones Triple P (SSTP) parenting therapy (nine weeks, six group sessions and three individualised sessions) in addition to Treatment as Usual
Trial: 32000729
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual only (other available services in each location)
Trial: 35812678
Drug: Psychosocial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychosocial intervention (administered in eight sessions biweekly over 4 weeks)
Trial: 39707490
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving antibiotics
Trial: 35738969
Drug: BCG intradermal
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG intradermal vaccine
Trial: 33486385
Drug: Cognitive‐behavioral group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral group therapy (CBGT) and Mindfulness‐based stress reduction (MBSR)
Trial: 32761337
Drug: Guilingji Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guilingji Capsules (GLJC) 0.6 g once a day and 19.2 mg of Gingko biloba extract mimetic 3 times a day
Trial: 32761337
Drug: Guilingji Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guilingji Capsules (GLJC) mimetic 0.6 g once a day and 19.2 mg of Gingko biloba extract in tablet form 3 times a day
Trial: 36161864
Drug: OMEGA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMEGA group (n = 14; 2234 mg of EPA and 916 mg of DHA daily)
Trial: 36161864
Drug: MCT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT group (n = 12; 4000 mg of MCT daily)
Trial: 33368399
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of volume as predictor for smaller lesions and selected features for larger lesions
Trial: 36206888
Drug: Imagery focussed
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagery focussed cognitive therapy (ImCT)
Trial: 34961942
Drug: 0.8% HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8% HA gel applied onto the collagen matrix three times per day for 7 days
Trial: 34961942
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No gel application
Trial: 36396084
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (660nm, 400mW/cm2, 300 seconds, methylene blue 0.01%)
Trial: 36396084
Drug: Mupirocin (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin (twice a day for 5 days)
Trial: 33074590
Drug: linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 5 mg/d
Trial: 34542305
Drug: Fluticasone propionate/Salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/Salmeterol (FP/Salm) with as-needed short acting beta-2 agonist (SABA)
Trial: 34542305
Drug: Budesonide/Formoterol (BUD/Form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/Formoterol (BUD/Form) Maintenance And Reliever Therapy (MART)
Trial: 36102582
Drug: Ultrasound-guided anterior
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided anterior quadratus lumborum block (LAL-QLB) with intravenous analgesia
Trial: 34049123
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of assertiveness training and SBAR technique
Trial: 35197082
Drug: Allopurinol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (20 mg/kg, administered intravenously in 2 doses early postnatally and 3 doses perioperatively)
Trial: 32029498
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg TXA
Trial: 36225762
Drug: Text4Hope intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Text4Hope intervention group (IG) receiving once-daily supportive text messages for 6 weeks
Trial: 36199051
Drug: Biomechanical markers
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomechanical markers (e.g., flexion during loading)
Trial: 32207709
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment complex (STC) + 5% brine electrophoresis by sinusoidal modulated currents, sage and sea baths
Trial: 32207709
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment complex (STC)
Trial: 35849214
Drug: Fast infusion
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast infusion of 20% albumin (3 mL/kg over 30 min)
Trial: 35849214
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion of 20% albumin (3 mL/kg over 120 min)
Trial: 35849214
Drug: Fast infusion
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast infusion of 20% albumin
Trial: 35849214
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion of 20% albumin
Trial: 33537000
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (CC) 50mg/day
Trial: 32103160
Drug: 30% oral
RxNorm normalized name: Lactobacillus Acidophilus/Lactobacillus Bifidus 70%-30% Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% oral dextrose
Trial: 32103160
Drug: 30% oral
RxNorm normalized name: Lactobacillus Acidophilus/Lactobacillus Bifidus 70%-30% Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% oral dextrose and facilitated tucking
Trial: 32062862
Drug: Exenatide extended
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide extended release 2 mg
Trial: 34571011
Drug: Wii Fit
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Wii Fit rehabilitation program (30 minutes) in addition to standard physical therapy program (SPTP) (60 minutes), 3 sessions a week for 12 weeks.
Trial: 34571011
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy program (SPTP) only, 3 sessions a week for 12 weeks.
Trial: 33429174
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (2 puffs of 100 µg once daily in each nostril for 3 weeks) with olfactory training
Trial: 33567890
Drug: Sumatriptan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (4 mg intravenous infusion over 10 min)
Trial: 33567890
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous infusion over 10 min)
Trial: 33122353
Drug: Experimental agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental agents with single-agent activity classified as active
Trial: 33122353
Drug: Inactive agents
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive agents
Trial: 33122353
Drug: Agents without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Agents without known single-agent activity (pooled inactive and indeterminate)
Trial: 35637106
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg caffeine capsule
Trial: 32078486
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel
Trial: 32352505
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment with 4 cycles of nivolumab and doxorubicin, vinblastine, and dacarbazine (N-AVD)
Trial: 32352505
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with 4 doses of nivolumab, 2 cycles of N-AVD, and 2 cycles of AVD followed by 30-Gy involved-site radiotherapy
Trial: 32352505
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy (4 doses)
Trial: 35193902
Drug: SPEAKS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SPEAKS intervention (weekly psychotherapy lasting nine to 12 months)
Trial: 33570488
Drug: Dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonists and clonazepam prescriptions
Trial: 33570488
Drug: Cumulative prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative prescription dose of medication
Trial: 34807760
Drug: PLG0206 (0.05,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLG0206 (0.05, 0.125, 0.25, 0.5, or 1 mg/kg)
Trial: 34807760
Drug: PLG0206 (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLG0206 (0.05 to 1.0 mg/kg)
Trial: 33270835
Drug: Internal Hexagon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal Hexagon (IH) connection implants
Trial: 33270835
Drug: Internal Conical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal Conical (IC) connection implants
Trial: 35280228
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of vitamin D3 supplementation
Trial: 35280228
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose (5,000 IU)
Trial: 35280228
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose (50,000 IU)
Trial: 35770374
Drug: Oral cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabis (0, 10 and 25 mg ∆9-THC)
Trial: 35770374
Drug: Vaporized cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaporized cannabis (0, 5 and 20 mg ∆9-THC)
Trial: 35770374
Drug: Vaporized cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaporized cannabis administration
Trial: 32443332
Drug: Acitretin Capsule
RxNorm normalized name: Acitretin Capsules
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin Capsule
Trial: 35801865
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored interventions (physical activity, cognitive behaviour therapy for insomnia, computerized memory training, cognitive behavioural therapy for self‐esteem)
Trial: 32756479
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily habits (Control Group)
Trial: 34585396
Drug: Ibudilast (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibudilast (50 mg, twice daily; n = 20)
Trial: 34585396
Drug: Ibudilast (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibudilast (50 mg, twice daily)
Trial: 36056577
Drug: PSA <3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA <3 ng/mL
Trial: 36056577
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA 0 to 0.99 ng/mL
Trial: 36056577
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA 1.0 to 1.99 ng/mL
Trial: 36056577
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA 2 to 2.99 ng/mL
Trial: 36056577
Drug: PSA <1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA <1 ng/mL
Trial: 36056577
Drug: PSA 2
RxNorm normalized name: Prednisolone Sodium Phosphate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PSA 2 to 2.99 ng/mL
Trial: 37949617
Drug: TIL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIL therapy
Trial: 32896456
Drug: qHBsAg <8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qHBsAg <8 IU/mL in training set
Trial: 32896456
Drug: qHBsAg <8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qHBsAg <8 IU/mL in validation set
Trial: 32896456
Drug: qHBsAg cutoff
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qHBsAg cutoff of 8 IU/mL
Trial: 32896456
Drug: qHBsAg cutoff
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qHBsAg cutoff of 200 IU/mL in training set
Trial: 32721845
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (20 mg/kg iv bolus before anesthesia induction followed by 20 mg/kg/h until surgery completion)
Trial: 34409931
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing integrated with cognitive behavioural therapy (MI-CBT)
Trial: 33597586
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA; 4 ml)
Trial: 34059848
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill (22%, n = 26/117)
Trial: 33404379
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to anti-vaccine comments
Trial: 33404379
Drug: Mainstream news
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainstream news article discussing the flu vaccine
Trial: 33995533
Drug: Chest-to-chest skin-to-skin
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest-to-chest skin-to-skin contact (CC-SSC)
Trial: 32380894
Drug: Glycopyrrolate metered
RxNorm normalized name: formoterol fumarate / glycopyrrolate Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate metered dose inhaler (GP MDI) 18 μg
Trial: 32380894
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg
Trial: 33932031
Drug: Nelfinavir (875
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir (875 mg orally twice daily)
Trial: 33932031
Drug: Nelfinavir (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir (1250 mg orally twice daily)
Trial: 33932031
Drug: Nelfinavir with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir with concurrent CRT
Trial: 32279561
Drug: First-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation drug-eluting stents (DES1)
Trial: 32279561
Drug: Second-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation drug-eluting stents (DES2)
Trial: 34915485
Drug: APF-gel application
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: APF-gel application (1.23% F applied for 4 min)
Trial: 36189647
Drug: Albuterol +
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol + Vasoactive
Trial: 32678131
Drug: Eyelid hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyelid hygiene performed twice a day for 10 days from 3 days before to 1 week after cataract surgery
Trial: 32431251
Drug: PROPER intervention
RxNorm normalized name: Propel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROPER intervention (structured and repeated multidisciplinary medication review, supported by education and continuous evaluation)
Trial: 36307616
Drug: Sclerotherapy (injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerotherapy (injections of ethanolamine oleate)
Trial: 32852613
Drug: Emixustat hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Emixustat (DB12608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emixustat hydrochloride (daily oral doses ranging from 5 to 40 mg for 84 days)
Trial: 35399053
Drug: 200 IU/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU/d vitamin D3 (control dose)
Trial: 33200813
Drug: Trimetazidine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (35 mg b.i.d.) on top of standard medical therapy
Trial: 34078209
Drug: Contextual interference
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contextual interference group who putted at varied putting distances and had varied repetitive weekly schedule patterns
Trial: 36448744
Drug: Topical Jessner
RxNorm normalized name: lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Jessner solution
Trial: 33029953
Drug: 4 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 × 30‐mg tablets
Trial: 33029953
Drug: 4 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 × 30‐mg tablets as slurry
Trial: 33063273
Drug: Plenadren (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plenadren (once-daily dual-release hydrocortisone)
Trial: 36115321
Drug: Testosterone administration
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone administration (single dose)
Trial: 32106877
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL pleural lavage fluid
Trial: 32106877
Drug: 3000 mL
RxNorm normalized name: TPN Bag 3000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mL pleural lavage fluid
Trial: 34969428
Drug: Medication event
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication event reminder monitor system (MERM) with treatment monitor
Trial: 34048682
Drug: Camidanlumab tesirine
RxNorm normalized name: Camidanlumab tesirine
DrugBank: Camidanlumab tesirine (DB16411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camidanlumab tesirine (3–150 μg/kg, administered intravenously once every 3 weeks)
Trial: 36726737
Drug: Benralizumab 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 100 mg
Trial: 36849212
Drug: Placebo (subcutaneous)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous)
Trial: 35906582
Drug: routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: routine oral care with rhIL‐11 mouthwash
Trial: 35906582
Drug: routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: routine oral care
Trial: 36473029
Drug: Crocin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocin (15 mg daily)
Trial: 36473029
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg daily)
Trial: 34343420
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of hypertonic saline (0.5 ml)
Trial: 34343420
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of hypertonic saline (1.0 ml)
Trial: 33116482
Drug: 1,100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,100 µg F−/g
Trial: 33116482
Drug: 1,100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,100 µg F−/g + nano‐HA
Trial: 33116482
Drug: 5,000 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 µg F−/g
Trial: 33116482
Drug: 5,000 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 µg F−/g + nano‐HA
Trial: 32306477
Drug: Faster aspart
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faster aspart (0.2 U/kg, single-dose subcutaneous)
Trial: 32306477
Drug: IAsp (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAsp (0.2 U/kg, single-dose subcutaneous)
Trial: 32004201
Drug: Rapid hemorrhage
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid hemorrhage (1.4 ml/min, 30‐min bleeding)
Trial: 32004201
Drug: Rapid‐L hemorrhage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid‐L hemorrhage (1.4 ml/min, 30‐min bleeding and observation until 6 h)